Ernexa Therapeutics (ERNAW) Accumulated Expenses (2010 - 2026)

Ernexa Therapeutics has reported Accumulated Expenses for 17 years, with the latest figure at $497000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 4041.67% year-over-year to $497000.0; the trailing twelve-month figure through Mar 2026 stood at $497000.0 (up 4041.67% YoY), and the FY2025 full-year result was $12000.0, down 98.81% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $497000.0, up from $12000.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $3.6 million in Q4 2022, with the low at $12000.0 in Q1 2025.
• Historically, Accumulated Expenses has averaged $1.1 million across 5 years, with a median of $859000.0 in 2025.
• Annual changes were most pronounced in 2025 — Accumulated Expenses tumbled 98.81% — and 2026, when it soared 4041.67%.
• Ernexa Therapeutics' Accumulated Expenses stood at $3.6 million in 2022, then tumbled by 96.99% to $109000.0 in 2023, then jumped by 823.85% to $1.0 million in 2024, then plunged by 98.81% to $12000.0 in 2025, then soared by 4041.67% to $497000.0 in 2026.
• The last three Accumulated Expenses figures came in at $497000.0 (Q1 2026), $12000.0 (Q4 2025), and $859000.0 (Q3 2025), per Business Quant data.